InflaRx schedules kidney data: Needham targets InflaRx stock at USD 8.00

Published on 10/15/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

InflaRx presents izicopan data on October 22, 2026, after 90.00 percent blockade. InflaRx stock costs EUR 1.33 on October 15, 2026 in trading.

Clinical milestones shape the outlook

InflaRx announced the kidney data poster on October 2, 2026, with the presentation scheduled for October 22, 2026.
Needham began coverage with a Buy rating and an USD 8.00 price target on September 14, 2026.
InflaRx stock was trading at EUR 1.33 at 12:59 p.m. CEST at Lang & Schwarz on October 15, 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx (ISIN NL0012661870) was trading at EUR 1.33 at Lang & Schwarz on October 15, 2026 at 12:59 p.m. CEST. The company is preparing a late-breaking kidney data poster for October 22, 2026, giving investors a defined clinical milestone to watch.

According to BioSpace, InflaRx announced on October 2, 2026 that izicopan had been selected for a late-breaking poster session at Kidney Week 2026 in Denver. The presentation is scheduled for October 22, 2026 and will address the oral C5a receptor 1 antagonist in kidney disease models.

What does the pipeline signal mean?

The available clinical evidence gives the poster a measurable starting point. InflaRx reported at least 90.00 percent blockade of C5a-induced neutrophil activation during 14 days of dosing, while the company also described no safety signals of concern in first-in-human and Phase 2a data, according to BioSpace. These are development indicators, not approval or revenue evidence.

Analyst target sets a wide spread

Needham initiated coverage on September 14, 2026 with a Buy rating and an USD 8.00 price target, as reported by TipRanks. The target is in US dollars and is not a euro price comparison. MarketBeat reported on October 13, 2026 that nine brokerages carried a combined Moderate Buy view with an average target of USD 7.43, while also noting mixed individual recommendations.

Three milestones define the chronology

On September 14, 2026, Needham opened coverage with an USD 8.00 target. On September 21, 2026, InflaRx scheduled a virtual capital markets event for November 3, 2026, according to StockTitan. On October 2, 2026, it announced the October 22 kidney poster, according to BioSpace.

Dates investors can mark

The next clinical date is October 22, 2026 for the Kidney Week poster. The next corporate event is November 3, 2026 for the virtual capital markets event, according to StockTitan.

Stock remains tied to clinical execution

InflaRx's valuation story is still centered on whether izicopan can convert pharmacology and early clinical observations into a clearer development path for ANCA-associated vasculitis and renal diseases. The October poster and November event therefore provide two separate dates for assessing how the company frames its program.

InflaRx was trading at EUR 1.33 at Lang & Schwarz on October 15, 2026 at 12:59 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of InflaRx stock.